After more than a decade of controversy, medical experts say that Hormone Replacement Therapy (HRT) for women in their 50s is safe in combating the menopause.

Taking medication to reduce the symptoms of the menopause is now deemed safe and the benefits for women on HRT are now thought to far outweigh the potential risks. Freshly released guidance from the British Menopause Society (BMS) has sought to reassure patients.

Medical experts say hundreds of thousands of women have suffered unnecessarily as a result of the decade-long controversy over the effects of HRT.

They say that General Practitioners (GPs) should prescribe the treatment to any woman who has unpleasant menopausal symptoms, such as hot flushes and mood changes. HRT is also known to provide bone protection in later life.

However, the debate over HRT use is likely to rage on as The Royal College of Obstetricians and Gynaecologists continues to advise HRT prescription only for women with serious menopausal symptoms ‘for the shortest time possible’.

After a period of five years doctors are not expected to continue prescribing HRT medication without discussing potential risks with their patients.

Uptake of HRT halved after two studies linked it to an increased risk of heart disease and breast cancer. An estimated one million women in the UK stopped having the treatment.

But the emerging consensus now is that the benefits of HRT outweighed the risks for most women, and that GPs should consider the updated BMS advice when treating the condition.

Consultant Endocrinologist Dr Helen Buckler, from the University of Manchester, speaking at the Cheltenham Science Festival, said the two studies linking HRT to breast cancer and heart disease were ‘scientifically unreliable’.

She said:

… The new advice is HRT should be used for a slightly wider age, if need be. If a woman has symptoms affecting the quality of her personal or professional life, then the benefits outweigh the risk.

The scare of taking HRT began in 2002, when the US Women’s Health Initiative study was halted some three years early because researchers claimed women using HRT were at a higher risk of breast cancer, heart disease and strokes. Yet, this contradicted previous (and later) research which suggested its use guarded against heart problems.

HRT is normally prescribed to menopausal women in their 50s, but according to the WHI study it was also given to women in their 60s and 70s who had gone through the menopause more than a decade earlier.

Shortly afterwards the UK Million Women Study, part funded by Cancer Research, a charity, said HRT doubled breast cancer risk, but a review in 2012 said it was ‘unreliable and defective’.

The advice from Cancer Research remains that there is still convincing evidence that women who take HRT have an increased risk of breast cancer. Dr Buckler, though, said the organisation was ‘out of step’ and its approach had tended to ‘put women off’ taking the treatment.

Some younger doctors have never prescribed HRT because they assume the risks outweigh the benefits.

Cancer Research UK said there was ‘convincing evidence’ that women who take HRT have an increased risk of breast cancer, but says that risk returns to normal around five years after the medication is stopped being used.

The BMS guidance is also opposed to the ‘arbitrary’ five year limit on treatment, and says it should be continued if symptoms persist.

The BMS, a registered charity and medical foundation, receives no government funding. Its medical advisory council comprises leading international experts in post reproductive health management, who regularly draw up guidelines for health professionals.